Mill Capital Management’s AbbVie ABBV Stock Holding History

Mill Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$830K	Sell	3,297 -1,125	-25%	-$242K	0.06%	83
2026 Q1	$962K	Hold	4,422	–	–	0.07%	80
2025 Q4	$1.01M	Buy	4,422 +40	+0.9%	+$9.11K	0.07%	81
2025 Q3	$1.01M	Hold	4,382	–	–	0.08%	78
2025 Q2	$813K	Hold	4,382	–	–	0.06%	81
2025 Q1	$918K	Hold	4,382	–	–	0.07%	81
2024 Q4	$779K	Hold	4,382	–	–	0.06%	82
2024 Q3	$865K	Hold	4,382	–	–	0.07%	81
2024 Q2	$752K	Hold	4,382	–	–	0.06%	84
2024 Q1	$798K	Hold	4,382	–	–	0.07%	85
2023 Q4	$679K	Hold	4,382	–	–	0.06%	89
2023 Q3	$653K	Hold	4,382	–	–	0.06%	89
2023 Q2	$590K	Hold	4,382	–	–	0.06%	92
2023 Q1	$698K	Hold	4,382	–	–	0.07%	86
2022 Q4	$708K	Hold	4,382	–	–	0.08%	83
2022 Q3	$588K	Sell	4,382 -198	-4%	-$28.4K	0.07%	85
2022 Q2	$701K	Hold	4,580	–	–	0.08%	82
2022 Q1	$742K	Buy	4,580 +198	+5%	+$28.8K	0.07%	89
2021 Q4	$593K	Buy	+4,382	New	+$518K	0.06%	78

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Mill Capital Management's ABBV Position: Q2 2026 in Review

Mill Capital Management reduced its AbbVie (ABBV) stake by 25% in Q2 2026, selling an estimated $242K and leaving 3,297 shares worth $830K. The position accounts for 0.06% of the portfolio, ranked #83.

Mill Capital Management first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.01M in Q3 2025. 4,225 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Mill Capital Management held 3,297 shares of AbbVie worth $830K as of Q2 2026.
Mill Capital Management sold 1,125 AbbVie shares in Q2 2026, an estimated $242K.
AbbVie made up 0.06% of Mill Capital Management's portfolio in Q2 2026, its #83 holding.
Mill Capital Management first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
Mill Capital Management's AbbVie position peaked at $1.01M in Q3 2025.
4,225 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Mill Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.